Categories Earnings, Health Care

Dynavax Technologies Corporation (NASDAQ: DVAX): Q4 2019 Earnings Snapshot

— Biopharmaceutical company Dynavax Technologies Corporation (NASDAQ: DVAX) reported a net loss of $36.8 million $0.44 per share for the fourth quarter of 2019, vs. $0.33 per share loss expected.

— Total sales more than doubled year-over-year to $10.57 million, vs. $11.96 million expected

— Research and development expenses dropped to $12.3 million in the fourth quarter from $22.9 million last year

— Established research collaboration with the University of Queensland and the Coalition for Epidemic Preparedness to develop coronavirus vaccine

— Appointed Ryan Spencer chief executive officer and to the board of directors; named David Novack president and chief operating officer

— Expects HEPLISAV-B net product revenue to increase to $55-$62 million in fiscal 2020

— On track to release interim data from ongoing study of HEPLISAV-B in hemodialysis patients in the first quarter

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Here’s a look at Dollar Tree’s (DLTR) expectations for the remainder of the year

Shares of Dollar Tree Inc. (NASDAQ: DLTR) were down over 1% on Wednesday, a day after the company reported earnings results for the third quarter of 2022. Revenue and earnings

Target Corporation (TGT): A look at how the retail giant is shaping up against an inflationary backdrop

Shares of Target Corporation (NYSE: TGT) were up over 1% on Wednesday. The stock has dropped 30% year-to-date and 35% over the past 12 months. Last week the company reported

Is Zoom Video Communications (ZM) a good investment after Q3 earnings?

Zoom Video Communications (NASDAQ: ZM) expanded its customer base at an accelerated pace during the COVID crisis and soon became the preferred video conferencing platform for businesses and millions of

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top